We previously reported that naive, tumor-specific CD8(+) (TcR-I) T cells transferred into prostate tumor-bearing mice traffic to the prostate where they become tolerized. We now report that TcR-I cells suppress the proliferation of naive T cells. This suppression is mediated at least in part by secreted factors, and the suppressive activity can be blocked by Abs directed against TGF-beta. We further report that TcR-I cells must infiltrate the prostate to acquire suppressive activity. Delivery of tumor-specific CD4(+) T cells prevents the conversion of TcR-I cells into suppressor cells. Taken together, our findings may have critical implications for sustaining T cell responsiveness during immunotherapy, as the development of suppressor cells in the tumor microenvironment may eliminate the potency of T cells primed in the periphery or delivered during adoptive immunotherapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948842 | PMC |
| http://dx.doi.org/10.4049/jimmunol.0900848 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dendritic cell-mediated responses to secreted Cryptosporidium effectors promote parasite-specific CD8 T cell responses.
Mucosal Immunol
June 2024
Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, USA. Electronic address:
Article Synopsis
- Cryptosporidium causes severe diarrhea in people with weakened T cell functions, making it hard to control the infection.
- Scientists engineered Cryptosporidium to express a protein that triggers T cell responses, leading to the expansion of specific CD8 T cells that produce interferon-gamma (IFN-γ) to help control parasite growth.
- The study shows that while the infection targets intestinal cells, the collaboration between these cells and type 1 conventional dendritic cells is essential for effective CD8 T cell responses against Cryptosporidium.
ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells.
Front Immunol
August 2022
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Breast tumors and their derived circulating cancer cells express the leukocyte β integrin ligand Intercellular adhesion molecule 1 (ICAM-1). We found that elevated ICAM-1 expression in breast cancer cells results in a favorable outcome and prolonged survival of breast cancer patients. We therefore assessed the direct contribution of ICAM-1 expressed by breast cancer cells to breast tumorigenesis and lung metastasis in syngeneic immunocompetent mice hosts using spontaneous and experimental models of the lung metastasis of the C57BL/6-derived E0771 cell line, a luminal B breast cancer subtype.
View Article and Find Full Text PDFAnti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Front Immunol
February 2022
Baylor Scott and White Research Institute, Dallas, TX, United States.
CD40 is a potent activating receptor expressed on antigen-presenting cells (APCs) of the immune system. CD40 regulates many aspects of B and T cell immunity interaction with CD40L expressed on activated T cells. Targeting antigens to CD40 agonistic anti-CD40 antibody fusions promotes both humoral and cellular immunity, but current anti-CD40 antibody-antigen vaccine prototypes require co-adjuvant administration for significant efficacy.
View Article and Find Full Text PDFSelective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
J Natl Cancer Inst
January 2015
Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Internal Medicine IV, Ludwig-Maximilians-Universität München, Munich, Germany (SK, JS, MiC, SG, JH, YZ, JCS, MS, SR, CB, SE); Roche Pharmaceutical Research and Early Development, Oncology Discovery and Translational Area, Roche Innovation Center Penzberg, Penzberg, Germany (RC, CS, GN); Center for Molecular Medicine Cologne and Department I for Internal Medicine, University Hospital Cologne, Cologne, Germany (MaC, HA); Institute of Molecular Immunology, Helmholtz Zentrum München and Clinical Cooperation Group Immune Monitoring, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany (DJS); Roche Pharmaceutical Research and Early Development, Oncology Discovery and Translational Area, Roche Innovation Center Zurich, Switzerland (CL); Chair of Pharmacology, Department of Medicine, University of Fribourg, Fribourg, Switzerland (CB).
Background: One bottleneck for adoptive T cell therapy (ACT) is recruitment of T cells into tumors. We hypothesized that combining tumor-specific T cells, modified with a marker antigen and a bispecific antibody (BiAb) that selectively recognizes transduced T cells and tumor cells would improve T cell recruitment to tumors and enhance therapeutic efficacy.
Methods: SV40 T antigen-specific T cells from T cell receptor (TCR)-I-transgenic mice were transduced with a truncated human epidermal growth factor receptor (EGFR) as a marker protein.
Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells.
J Immunol
October 2009
Tumor Immunity and Tolerance Section, Laboratory of Molecular Immunoregulation, Cancer and Inflammation Program, National Cancer Institute-Frederick, Frederick, MD 21702, USA.
We previously reported that naive, tumor-specific CD8(+) (TcR-I) T cells transferred into prostate tumor-bearing mice traffic to the prostate where they become tolerized. We now report that TcR-I cells suppress the proliferation of naive T cells. This suppression is mediated at least in part by secreted factors, and the suppressive activity can be blocked by Abs directed against TGF-beta.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!